[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615325":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":11,"centralContacts":15,"locations":20,"responsibleParty":38,"collaborators":42,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":84,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Linkoeping University","OTHER_GOV",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Adult patients with liver cirrhosis without prior hepatocellular carcinoma",null,[12],{"name":13,"affiliation":5,"role":14},"Mattias Ekstedt, MD, PhD","PRINCIPAL_INVESTIGATOR",[16],{"name":13,"role":17,"phone":18,"phoneExt":10,"email":19},"CONTACT","0046709296267","mattias.ekstedt@liu.se",[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Department of gastroenterology and hepatology, University hospital in Linköping","RECRUITING","Linköping","Select A State Or Province","S-58931","Sweden","SE",{"type":30,"coordinates":31},"Point",[32,33],15.62157,58.41086,{"lat":33,"lon":32},[36],{"name":13,"role":17,"phone":37,"phoneExt":10,"email":19},"+46709296267",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Mattias Ekstedt","Consultant\u002FSenior associate professor",[43,46,48,51,53,55,57,59,61],{"name":44,"class":45},"Antaros Medical","INDUSTRY",{"name":47,"class":45},"Amra Medical AB",{"name":49,"class":50},"Region Östergötland","OTHER",{"name":52,"class":6},"Region Jönköping County",{"name":54,"class":50},"Västra Götalandsregionen",{"name":56,"class":6},"Region Stockholm",{"name":58,"class":6},"Örebro County Council",{"name":60,"class":6},"Uppsala County Council, Sweden",{"name":62,"class":50},"University Hospital, Umeå","100615325","a-comparative-study-of-mri-and-ultrasound-for-detection-of-primary-hepatocellular-carcinoma-body-composition-and-risk-factors-for-decompensation-in-liver-cirrhosis-100615325",false,"NCT07291141","A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis","DETECT-HCC","Inclusion Criteria:\n\n* Patients with liver cirrhosis, according to clinical practice. Based on criteria such as elastography, symptoms, biopsy, or radiology.\n* Age ≥18 years ≤ 84\n* Written informed consent from the participant\n\nExclusion Criteria:\n\n* Contraindications for MRI (ferrrous material, claustrophobia)\n* Pregnancy\n* Diagnosis of primary sclerosing cholangitis (PSC)\n* Vascular liver disease\n* Congenital liver fibrosis\n* Previous diagnosis of hepatic carcinoma (HCC)\n* Previous liver transplant","ALL","18 Years",{"count":73,"type":74},600,"ESTIMATED","OBSERVATIONAL","DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals.\n\nA key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability.\n\nThe protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk.\n\nLongitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories.\n\nThe DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.",[78,79,80,81,82,83],"Liver Cirrhoses","Hepatocellular Carcinoma (HCC)","Sarcopenia in Liver Cirrhosis","Portal Hypertension Related to Cirrhosis","MRI","Ultrasound",[85,86,87,88],"Abbreviated MRI","Hepatocellular carcinoma","Liver cirrhosis","Sarcopenia","2025-12-18",{"date":91,"type":92},"2025-12-19","ACTUAL",{"date":89,"type":92},{"date":95,"type":74},"2031-12",{"name":40,"class":6},1]